The Journal of Antimicrobial Chemotherapy (JAC) is among the foremost international journals in antimicrobial research. Our readership includes representatives of academia, industry and health services, and includes those who are influential in formulary decisions. JAC is included in over 3700 consortia subscriptions that span institutions across the globe. Published monthly, the Journal features original articles on the laboratory aspects and clinical use of antimicrobials including antibacterial, antiviral, antifungal, and antiprotozoal agents and each issue contains Editor's Choice papers, which are open access to all, offering true value to the scientific, research and healthcare communities. In addition to the wealth of primary papers, the journal carries review articles offering in-depth discussion on matters of topical concern. Lively leading articles offer incisive coverage of recent advances and controversies.
JAC-Antimicrobial Resistance is the newest addition to BSAC’s stable of academic journals, committed to publishing clinically oriented opinions, reviews and original articles that advance the science and knowledge of antimicrobial resistance, alongside peer review commentaries on stewardship resources. As the foremost global health issues of our time, antimicrobial resistance requires an innovative, interdisciplinary response, which goes beyond traditional microbiology. By providing a diverse cross-section of articles from a broad spectrum of specialities, JAC-AMR provides cutting edge research into the treatment and prevention of difficult-to treat infections around the world. Meanwhile, JAC-AMR’s innovative online repository for educational resources helps support learning and increase knowledge about antimicrobial stewardship practice, antimicrobial resistance, behaviour change and more, for a worldwide audience.